Webinar: Restoring 340B Accountability: What New Evidence Reveals About 340B Hospitals, Reimbursement Gaps, and Rising Costs

On March 25th, ASAP 340B hosted a webinar with our coalition partners AiArthritis, the Autoimmune Association, and National Consumers League to spotlight new findings on reimbursement disparities for autoimmune therapies between 340B and non-340B facilities, medical debt among patients at 340B hospitals, and the broader unintended consequences the program’s evolution is creating for employers, taxpayers, and healthcare providers.  

The panel of experts included:

• Thomas Johnson, Executive Director, ASAP 340B 

• Amanda Krzepicki, Policy Director, Autoimmune Association

• Mark Hobraczk, Director of Public Policy, AiArthritis

• Lisa Bercu, Senior Director of Health Policy, National Consumers League

ASAP 340B is encouraged to see our partners advancing the need for federal 340B reform through robust, meaningful research that highlights how the program has strayed from its original intent of serving vulnerable patients and calling out instances of 340B misuse by certain entities.

Learn more from their research below.

• Unintended Consequences: How the 340B Program Impacts Patients Across the Healthcare System

• Variations in outpatient hospital reimbursement for autoimmune drugs: An analysis of hospital price transparency data

• Hospital Medical Debt: Aggressive Debt Collection Practices in 340B Hospitals Despite Higher Cancer Burdens.

In case you missed it, please see below for the full recording.

https://video.wixstatic.com/video/476dfb_809a987855f94ea8a31e25475d6d3ff2/1080p/mp4/file.mp4